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Autoimmune Connective Tissue Disorders 
have rarely been reported among African 
blacks and even in Nigeria, in contrast with 
African-Americans. Our encounter with 
these cases shows that the disease may not 
be rare after all. The objective of this study 
was to report the prevalence, clinical 
presentations, laboratory and serological 
characteristics of patients presenting with 
autoimmune connective tissue disorders in 
the University of Port-Harcourt Teaching 
hospital. 
METHOD 
This was a retrospective study of patients 
presenting with autoimmune disorder 
attending the Rheumatology and 
Dermatology clinic in University of Port 
Harcourt Teaching Hospital, Port 
Harcourt, located in Rivers state, South-
South, Nigeria, over a period of one year 
(2012-2013). A review of the case records of 
all patients diagnosed and treated for 
autoimmune connective tissue disorders 
was utilized using the American College of 
Rheumatology Criteria for Systemic Lupus 
Erythematosus, Systemic Sclerosis and 
Rheumatoid Arthritis. 
RESULTS 
Our study indicates that out of 931 
Rheumatology/Dermatology cases seen, 30 
were autoimmune connective disorders 
indicating a frequency of 3.2%. Out of this 
3.2%, Systemic lupus erythematosus (SLE) 
constituted about 91%, rheumatoid 
arthritis 6% and systemic sclerosis 
constituted about 3%. The age range of the 
subjects was between 14-59years with a 
mean age of 34years, indicating the 
universal young age at presentation. 
Females constituted females 93.3% of the 
patients with a female to male ratio of 14:1. 
The duration of disease ranged from (0.1-15 
years) with a mean of 5years. The most 
clinical presentation of systemic lupus was 
discoid rash constituting about 93%, while 
that from rheumatoid arthritis was 
deformities of the proximal 
interphalangeal and distal 
interphalangeal joints. The maJor causes of 
mortality for the SLE patients were lupus 
nephritis, congestive cardiac failure and 
pulmonary hypertension, while death from 
systemic sclerosis was mostly linked to the 
renal crises. Rheumatoid factor was 
positive in 28 (93.3%), while Anti 
Neutrophilic Antibody was positive in 8 
(26.6%) of the tested subjects. 
CONCLUSION 
Autoimmune disorders may not be 
uncommon in Port-Harcourt, Nigeria, 
contrary to previous reports, as both the 
prevalence and incidence are rising 
probably due to increasing awareness and 
better diagnostics. Age, gender and 
ethnicity may also account for the risk 
factors. This is the first study to report 
prevalence of autoimmune connective 
disorders in Port-Harcourt, Rivers State. 
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INTRODUCTION 
Connective tissue diseases are a group of 
rheumatologic diseases which are 
autoimmune in nature and include 
Rheumatoid Arthritis, Systemic Lupus 
Erythematosus, Scleroderma, Mixed 
connective tissue disease, Dermatomyositis, 
Polymyositis and Sjogrens amongst others 1• 
Connective tissues are the structural portions 
of the body that essentially hold the cells of the 
body together. These tissues form a 
framework, or matrix, for the body and are 
composed of two major structural protein 
molecules, collagen and elastin. 
Autoimmunity has been considered to 
represent disorders associated with reaction of 
the patient's own immune system against self-
antigens or body systems. These diseases 
feature abnormal immune system activity 
with inflammation in tissues as a result of an 
immune system that is directed against one's 
own body tissues (autoimmunity) and are also 
referred to as systemic autoimmune diseases 2 • 
In many of these disorders, the tissues 
involved show lesions or morphology 
indicating destructive inflammatory or 
reactive features clearly produced by or 
associated with cell-mediated or antibody-
driven reactions of the patient against his own 
tissues. 1 
Systemic lupus erythematosus (SLE) is 
recognized more often in African blacks who 
have a younger age of onset and a confirmed 
genetic association with HLA DR43• Features 
such as photosensitivity and serositis are less 
common in blacks while renal disease which is 
more common makes the early screening for 
renal disease importane. 
The reported prevalence of systemic lupus 
erythematosus (SLE) in the world population 
is 20 to 150 cases per 100,0004 • The prevalence 
is known to be higher in women with varying 
rates from 164/100,000 in whites to 
406/100,000 in African Americans4 • 
The prevalence of SLE is higher among 
Asians, Afro-Americans, Afro-Caribbeansand 
Hispanic Americans compared with 
Americans of European descent in the United 
States, and among Asian Indians compared 
with Caucasians in Great Britain 5• 
Due to improved detection of mild disease, the 
incidence nearly tripled in the last 40 years of 
the 20th century\ consequently the disease 
appears to be more common in urban than 
rural areas. 
Although data on the prevalence of SLE 
among Africans and Asians living in the 
tropics are limited, SLE is more severe in 
people of African and Asian extraction 
compared to Europeans5.The high prevalence 
of SLE in recent migrants from West Africa 
also suggests that the disease is not rare in 
West Africa, and that there is a genetic basis 
for the high risk of SLE in people of West 
African descent compared with other groups6• 
In Ghana, a retrospective study over a 6 year 
period in a tertiary hospital recorded llcases 
of SLE out of 25 Rheumatology cases with the 
majority of the cases being females 7• 
Frasier et al, in Cote d I voire, reviewed a total 
of 9 cases seen over an 11 year period in a 
tertiary hospital using a retrospective 
analysis. All patients seen were females, aged 
between 20-40 years 7• 
In Zimbabwe, a prospective analysis in a 
hospital survey by Malembaet al8 over a 13 
year period showed 18 patients with SLE out 
of 141 (13%) rheumatology cases seen with 
females making up the majority of the 
subjects. Malemba et al thus suggested that 
SLE was not rare in Africa8.1n Kinshasa 
Congo, a retrospective hospital study of 
connective tissue disease done by Malemba et 
al in 2008 reported that SLE constituted up to 
5.2% of the 12.1% rheumatologycases9• 
In the same vein and with similar outcomes to 
the study by Malemba et al; a study done by 
Adelowo et al at the Athrimed hospital Lagos 
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revealed that SLE accounted for 5.28% of the 
1,250 rheumatology cases seen over the study 
period of 6 years (2000-2006). Females 
constituted 95.5% of the 66 cases seen. The 
subjects were aged 17-55 with a mean of 33 
years at presentation and had the symptoms 
for a mean of2.6 years 10• 
In the same way, Rheumatoid arthritis (RA) 
once a rarity in Africa, has now been reported 
inAfrica.2 
The prevalence of rheumatoid arthritis (RA) is 
relatively constant in many populations, at 
0.5-1.0%2'3.Although epidemiological surveys 
have shown that the prevalence in urban 
populations of Africa is similar to that in 
western communities, it is less common in 
rural areas2• Further epidemiological studies 
are needed to confirm these findings and 
identify factors contributing to this difference 
in order to provide a better understanding for 
the emergence of RA in Africa. Especially as 
studies in rural African populations, both in 
South Africa and in Nigeria, have failed to find 
any cases of RA in studies of 500 and 2000 
adults, respectively. 2 
Studies in populations from Southeast Asia, 
including China and Japan, have similarly 
shown very low occurrences (0.2-0.3%) for RA. 
In terms of gender, a similar pattern is seen 
worldwide, affecting females three times more 
commonly than men 11 • The cases of 
rheumatoid arthritis are more common among 
persons aged between 40 and 65 years 11 • 
A study from Nigeria by Adelowo12 showed a 
prevalence of 12.3% out of the 1,623 patients 
attending a private rheumatology clinic in 
Lagos over a period of 7 years (2001-2008). 
Females were more affected in the ratio 2.4:1, 
with a mean age of 46.9 years. The duration of 
symptoms ranged from 4-264 months with the 
proximal interphalangeal joint as the mostly 
affected site12• 
Systemic scleroderma on the other hand, 
usually develops between the ages of 35 and 
5512• Localized scleroderma is more common in 
children than adults, but is extremely rare 
even in the young age group. It occurs in 
between 0.2 and 0.4 per 100,000 people. 
Systemic scleroderma in children is even 
rarer14• 
The infrequent occurrence of systemic 
sclerosis worldwide has also been noted, 
although the localized type occurring with the 
absence of anti-centromere antibodies in 
blacks was noted in a recent large series in the 
western world3, in our environment not much 
work has been done on this. But the outcome of 
this disease is still very poor which may be 
attributed to a lot of factors such as lack of 
awareness of the disease, poor access to health 
facilities, illiteracy and poverty3 • 
Worldwide, the incidence of scleroderma is 
three to eight times higher in women than in 
men. Of possible importance was a 2002 study 
reporting that the disease tended to be less 
severe in women who developed it in middle 
age after being pregnant. 8 
A retrospective study by Adelowo9 also showed 
scleroderma prevalence of 1.1% out of 1,250 
rheumatology cases over a 5-year period 
(2001-2006) with a total of 14 cases. The 
majority (12) 85.7% of the patients were 
females compared to males(2)14.3%. The age 
range of the cases was between 26-69 years 
with a mean of 40.3years9 • 
The outcome of the studies on connective 
tissue diseases in Africa and Nigeria as 
reviewed above show's that Autoimmune 
Connective Tissue Diseases are not as rare as 
previously thought in Nigeria. In spite of this 
situation, there are few studies which have 
documented the National epidemiology and 
trend of these diseases. Reports on the 
epidemiology and profile on these conditions in 
Port Harcourt are also a rarity. It is on this 
background that this study aims to determine 
the profile and pattern of Autoimmune 
Connective Tissue Disorder in University of 
Port Harcourt Teaching over a one year period 
from January 2012- January 2013. 
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METHODOLOGY 
Study Site 
The study was carried out in the department of 
internal medicine of the University of Port-
Harcourt Teaching Hospital. The hospital 
serves as the main tertiary centre for Rivers 
State and the neighbouring South-South 
States of the Niger Delta. Rivers State has a 
heterogenous population of about 5.1million, 
(according to the national population census 
2006) consisting of several tribes as well as 
foreigners involved in the various economic 
activities in the area with many engaged in the 
oil and gas sector. 
In this study, we investigated the prevalence of 
Autoimmune Connective Tissue Disorders for 
a period of one year from 2012 -2013. First, we 
assessed whether there was any gender or age 
predilection. Next, we assessed the serological 
markers, clinical features, mean disease 
duration and overall clinical outcome 
Study Design and Population 
This was a cross-sectional retrospective study. 
The study population consisted of patients 
who had been diagnosed with having Systemic 
Lupus Erythematosus, Rheumatoid Arthritis 
and Scleroderma, fulfilling the American 
Rheumatology Criteria15'16'17( as in Tables 1, 2 
and 3 respectively) attending the Medical Out 
Patient Clinics and on admission in the 
medical wards of UPTH and also referred 
from other out-patient clinics. The data of 
patients who fulfilled the criteria of the 
American College of Rheumatology15'16'17for 
Systemic lupus, Rheumatoid Arthritis and 
Systemic Sclerosis were included in the study. 
Ethical approval was obtained from the ethical 
committee of the UPTH for the study. 
RESULTS 
A total of 931 Dermatology/ Rheumatology 
cases were seen, out of which 30(3.2%) cases of 
Autoimmune Connective Tissue Disorders 
treated in the hospital were reviewed. 
Out of the 30 patients, 27(91 %) of these 
patients fulfilled the American Criteria for 
Rheumatology for Systemic Lupus 
Erythematosus, 2(6%) fulfilled the American 
College of Rheumatology for Rheumatoid 
Arthritis and 1(3%) fulfilled the American 
College for Rheumatology for Sclerodermasee 
(Table 4). There was a significance difference 
in sex, age, clinical features and laboratory 
markers reviewed in these patients see (Table 
5). 
Table 1: ARA Criteria for the diagnoses of 
SLE15 
FEATURES DESCRIPTION SENSITIVITY SPECIFICITY 
Malar rash Rash on cheek 57% 97% 
Discoid rash Scalvrash 18% 99% 
Serositis Pleurisv/pericarditis 56% 86% 
Oral ulcers meers on mouth 27% 96% 
Arthritis Non-erosive 86% 37% 
Immunologic Anti-sm, Anti ds DNA, serology 85% 93% 
syphilis test 
Photosensitive 43% 96% 
ANA test 99% 49% 
CNS disorders Seizures/psychosis 20% 98% 
Renal >0.5f(//day protein 51% 94% 






in the absence of offendilll( drul! 
*CNS(Central nervous system); 
ANA(Antineutrophilic antibody); sm(Smith); 
ds(double stranded); DNA(Deoxyribonucleic 
acid); Hb(haemoglobin)}. To make a diagnosis, 
the patient should fulfil4 out of the 11 clinical 
features. 
Table 2 · American College of Rheumatology 
Criteria For Rheumatoid Arthritis.15 
Four of the following must be present in a 
minimum of six weeks 
Early morninl( stiffness l(l'eater than one hour 
Arthritis of 3 or more joints of the following; right or left proximal 
interphalangeal joints, elbows, 
Metarcarpophalangeal joints, wrist, knee, ankle and metartarsophalangeal 
I ioints. 
Symmetric involvement ofioints 
Rheumatoid nodules on bony prominences or extensor surfaces or in 
I juxtaarticular recions 
Positive serum rheumatoid factor 
Radiographic changes including erosions or bony decalcifications localized in or 
adjacent to the involved joint 
Arthritis of wrist, proximal interohalanl!eal ioint or metarcarpophalanl(eal joint 
Table 3 · Criteria For Diagnosing 
Scleroderma -1980 Criteria for the 
Classification of Systemic Sclerosis. 
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In this profile study however, we found out 
that autoimmune connective disorders have 
been under diagnosed previously in our 
environment. Systemic lupus erythematosus 
(SLE) constituted about 91%, rheumatoid 
arthritis 6% and systemic sclerosis constituted 
about 3%. The age range was between 14-
59years with a mean age of34years, indicating 
the universal young age at presentation, 
although 3 of the patients were elderly lupus 
at ages above 50. 
Most of the patients 93.3% were mostly 
females with a ratio of 14:1 while the disease 
duration in this study ranged from (0.1-15) 
with a mean of 5years. The finding of our 
study is similar to the worldwide prevalence of 
females being more affected with the age 
range ofbetween 15-50 years21 • 
SLE was the most common (91 %) autoimmune 
connective tissue disorder diagnosed in this 
study. This finding is similar to a retrospective 
study in Ghana which recorded 11cases ofSLE 
out of 25 Rheumatology cases7• Though the 
study by Adelowo et al in Lagos Nigeria 
revealed that SLE accounted for 5.28% of the 
1,250 rheumatology cases11, the difference may 
be explained by the smaller study size and 
shorter duration of our study. The observed 
high prevalence in this study may also be due 
to the increasing awareness among physicians 
and availability of better diagnostic facilities. 
In addition the fact that this study was a 
tertiary hospital survey may suggest that true 
prevalence of this condition may even be 
higher as many patients may be misdiagnosed 
and not referred. We therefore conclude that 
there is enough evidence that SLE IS 
significantly prevalent in our environment. 
The most common presentation of SLE was 
discoid and malar rash constituting about 93% 
and 33% respectively. This was also similar to 
the work done in kenyetta hospital in which 
malar rash actually constituted one of the 
major features22• Interestingly, most of the 
patients that had discoid and malar rash did 
not have any other clinical sign on 
examination but had additional laboratory 
investigations which made up the 4 out of the 
11 criteria for diagnosis. No patient had a 
mixed type of autoimmune connective tissue 
disorder. In addition to this, most patients 
presented with non-specific malaise and low 
grade fever across the 3 types of autoimmune 
disorder. Only one case of a male presenting 
with SLE was seen. The male patient also had 
malar rash and discoid rash in addition to and 
oral lesions on examination, with a positive 
ANA. The high female predominance seen in 
this study in line with findings from other 
studies3'4'10'11 and has been attributed to the 
presence of the female hormone oestrogen. 23 
The mean year of symptom duration seen in 
SLE patients was about five years. This 
duration of disease before presentation 
demonstrates the chronic course of SLE. 
Though Adelowo et al11 showed a prevalence of 
2.6 years in a report of the pattern of SLE 
among Nigerians, the difference in the mean 
year of symptom duration may be explained by 
the fact that the above cited study by Adelowo 
et al11 was done in a private specialist 
rheumatology clinic with the possibility of 
earlier referrals to this centre. 
The positive rates for both rheumatoid factor 
and erythrocyte sedimentation rate seen in 
this study indicate the importance of these two 
laboratory findings in patients with 
autoimmune connective tissue disorders. This 
same trend has been established in other 
studies.24'25 The high positive rates for ANA in 
patients diagnosed with SLE in this study also 
mirrors the established trend and makes it a 
useful tool in SLE diagnosis. 25-28 
Most of the SLE patients were on treatment 
with prednisolone, azathioprine and 
hydroxychloroquine, in addition to drugs for 
the treatment of other comorbidities like 
hypertension. A study by Marie et al in Douala 
Cameroon also showed that SLE patients 
benefitted from using steroids, 
immunosuppressives and antimalarias. 29 This 
is also in line with the European League 
Against Rheumatism (EULAR) for the 
treatment of SLE as patients without major 
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organ involvement will benefit from taking 
steroids and antimalarials but 
immunosuppressives should be taken in 
refractory cases and patients with major organ 
involvemene0.1t should however be noted that 
in patients with retinitis antimalarial should 
be avoided. One of the patients in this study, 
who had retinitis, was exempted from taking 
hydroxychloroquine. 
Only one case of scleroderma in a female was 
seen in this study. This prevalence of 3.3% of 
all rheumatologic conditions seen in this study 
made scleroderma the rarest of the 
rheumatologic disorders. This finding is 
similar to the study in western Nigeria done by 
Adelowo et aF6 that reported scleroderma as a 
rare disease in Nigerians. 
The prevalence of rheumatoid arthritis found 
in this study was 6. 7% of all rheumatologic 
diseases. The subjects were all females; who 
had all the six criteria of American College of 
Rheumatology criteria in addition to positive 
tests for anti-citrullated peptide and features 
of erosive arthritis of the knee on x-ray. Our 
findings on Rheumatoid Arthritis which 
indicate a delayed presentation with the 
presence of destructive changes is similar to 
what Adelowo16 et al and Wadee et al 31 found. 
The results of this study indicate that 
connective tissue diseases are more prevalent 
than previously thought in our environment. 
However, the limitation of this study is that, it 
covered only a 12month study period, which 
may be inadequate to investigate the profile of 
these disorders. The short period of review 
may also be responsible for the small number 
of patients seen within this period. The small 
sample size may have also resulted in an 
underestimation of the true burden of these 
diseases. 
The outcome of this study has shown that it is 
important to study the profile of these 
disorders in order to determine the current 
prevalence of these disorders, rather than 
relying on outdated estimations. The results of 
recent prevalence evaluation from studies like 
this will also be useful in evaluating any 
associated risks in this environment as 
compared to other regions within the country 
as well as other countries. 
There is need for higher index of suspicion and 
early referrals to improve probable 
underdiagnoses and late presentation. More 
public and physician education is 
recommended in order to promote early 
diagnosis and early referrals in addition to 
changing perceptions on these diseases as 
incurable diseases which defy medical care 
and treatment. 
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